Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of ZIOPHARM Oncology, Inc. (ZIOP) was $5.71. Currently, the 1st Resistance Point for this stock is $5.79, with a 2nd Resistance Point sitting at $5.87. Meanwhile, this company’s stock has a 1st Support Level at $5.60 and a 2nd Support Level at $5.48. ZIOPHARM Oncology, Inc. (ZIOP) stock has lost -$0.17, or -2.89%, in the past five days. In the last full month, these shares have gained $0.82, or 16.77%. In the past three months, this stock’s price has risen by $1.51, or 35.95%. This year-to-date, ZIOPHARM Oncology, Inc. (ZIOP) shares have gained $3.84, or 205.35%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For ZIOPHARM Oncology, Inc. (ZIOP) stock, 20% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 25% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 67% of long-term indicators suggest that this stock is a “ Buy .”
With 161,319 K shares outstanding, this company currently has a market capitalization of $921,132K. ZIOPHARM Oncology, Inc. (ZIOP) generates $150 K in annual sales, amounting to annual net income of -$53,120 K. This stock has generated a 1-Year Total Return of 82.43%, a 3-Year Total Return of 13.97%, and a 5-year Total Return of 73.03%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.08 per share. This estimate came from a total of 3 Wall Street Analysts. Of those market experts, the high estimate was -$0.07 and the low estimate was -$0.09. In the year-ago quarter, ZIOPHARM Oncology, Inc. (ZIOP) generated per-share earnings of -$0.12. If the analysts are correct about the current quarter’s earnings, the growth will be +33.33% .
Turning our focus now to insider trading activity, there have been 1 purchases (15,000 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 1 insider buys amounting to 15,000 shares and 0 insider sales amounting to 0 shares. In the past full year, 8 insider purchases were made (involving 1,232,719 shares) and 8 insider sell-offs equivalent to 294,848 shares.
Moving onto liquidity, ZIOPHARM Oncology, Inc. (ZIOP) has a Current Ratio of 8.89, a Quick Ratio of 8.89 and a Cash Ratio of 6.51.